Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.29), $0.11 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $94.6 million versus the consensus estimate of $88.49 million.

“We took a major step forward in fulfilling our mission to improve the lives of patients and their caregivers living with CNS disorders this quarter,” said Steve Davis, ACADIA’s Chief Executive Officer. “More patients are receiving NUPLAZID treatment for their Parkinson’s disease psychosis than ever before and I am proud to report that our commercial efforts drove strong financial performance with net sales of $94.6 million in the quarter, representing a 62% increase year-over-year. For patients and their families struggling with dementia-related psychosis (DRP), we believe, based on the robustly positive HARMONY Phase 3 data, that pimavanserin has the potential to be one of the first new treatments approved for people with dementia in over fifteen years and the first ever FDA-approved treatment for DRP.”

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.